{
    "clinical_study": {
        "@rank": "125988", 
        "acronym": "ParoPAR", 
        "arm_group": [
            {
                "arm_group_label": "patient with parodontitis", 
                "arm_group_type": "Other", 
                "description": "Patient with rheumatoid arthritis and pparodontitis."
            }, 
            {
                "arm_group_label": "Patient without parodontitis", 
                "arm_group_type": "Other", 
                "description": "Patient with rheumatoid arthritis but periodontally healthy"
            }
        ], 
        "brief_summary": {
            "textblock": "Rheumatoid arthritis and periodontitis are two inflammatory diseases that share many\n      pathophysiological similarities as some inflammatory mediators like TNF-alpha, IL-1, Il-6,\n      Il-17, Il-12 et Il-17, RANK-L, or OPG The most severe or progressive forms of rheumatoid\n      arthritis require in 10-30% of cases, the use of biotherapies such as anti-TNF-alpha, anti\n      CD-20 and anti-lL-6. All these treatments results in, among other things, an increased risk\n      of infection, both viral and bacterial.\n\n      These new biotherapies could have an impact on periodontal status\n\n        -  either by favouring sub gingival colonization of root surfaces by periodontal\n           pathogenic bacteria and initiate periodontitis or exacerbate pre-existing\n           periodontitis,\n\n        -  or a positive modulation of the host response by inhibiting bone resorption of the\n           alveolar process.\n\n      To date, very few studies have been conducted on this subject which is really a\n      translational research, involving several medical specialties."
        }, 
        "brief_title": "Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Rheumatoid Arthritis", 
            "Periodontitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid", 
                "Inflammation", 
                "Periodontal Pocket", 
                "Periodontitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patient over 18 years presenting a rheumatoid arthritis and for which an anti IL6\n             biotherapy treatment is prescribed.\n\n          -  At least 18 permanent teeth in the mouth at least 3 teeth with a healthy periodontal\n             status\n\n          -  Having expressed their written free and informed consent\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity to any of the following components : tocilizumab, saccharose,\n             polysorbate 80, phosphate disodique dod\u00e9cahydrate, phosphate monosodique dehydrate\n\n          -  Severe or active infections\n\n          -  Systemic Pathology affecting the immune system including Sj\u00f6gren's syndrome\n\n          -  Surgery in the previous month\n\n          -  HIV positive\n\n          -  Alcoholic\n\n          -  Toxicoman\n\n          -  Antibiotic treatment in the last 2 months\n\n          -  Legally protected patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806974", 
            "org_study_id": "RC12_0172"
        }, 
        "intervention": {
            "arm_group_label": [
                "patient with parodontitis", 
                "Patient without parodontitis"
            ], 
            "description": "The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.", 
            "intervention_name": "oral exam and", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Periodontitis", 
            "rheumatoid arthritis", 
            "anti-interleukin 6", 
            "immunotherapy", 
            "inflammation", 
            "bacteria", 
            "periodontal sulci", 
            "periodontal pockets"
        ], 
        "lastchanged_date": "September 2, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Julien DEMOERSMAN"
                }, 
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France"
                    }, 
                    "name": "Brest University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Jacques-Olivier PERS", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Julien DEMOERSMAN", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Alain SARAUX", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "assem.soueidan@chu-nantes.fr", 
                    "last_name": "Assem SOUEIDAN"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France"
                    }, 
                    "name": "Nantes University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Yves MAUGARS", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Zahi BADRAN", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "C\u00e9line BORIES", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jean Marie BERTHELOT", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jo\u00eblle GLEMAREC", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Assem SOUEIDAN", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Prospective Study, on the Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on: - Healthy and Pathological Periodontium - The Level of Expression of Some Markers of Inflammation and Periodontal Pathogenic Bacteria in Periodontal Sulci and Periodontal Pockets", 
        "overall_contact": {
            "email": "assem.soueidan@chu-nantes.fr", 
            "last_name": "Assem SOUEIDAN, PhD"
        }, 
        "overall_official": {
            "affiliation": "Nantes UH", 
            "last_name": "Assem SOUEIDAN", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "FRANCE : ANSM (Agence National de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Gain or loss obtained by periodontal probing.", 
            "measure": "Clinical attachment level", 
            "safety_issue": "No", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806974"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Detection of periodontopathogenic germs by RT - PCR - Q wich the bacterial samples will be made at the outset of the study and 6 month after the beginning of anti IL6 treatment.", 
                "measure": "Detection of periodontopathogenic germs", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "description": "Quantification of periodontopathogenic germs by RT - PCR - Q wich the bacterial samples will be made at the outset of the study and 6 month after the beginning of anti IL6 treatment.", 
                "measure": "Quantification of periodontopathogenic germs", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "description": "Detection and quantification of inflammation markers in the gingival fluid : IL-1, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, TGF- beta, TNF-alpha, IL-4 et IFn-gamma.", 
                "measure": "Detection of inflammation markers in the gingival fluid", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "description": "Quantification of inflammation markers in the gingival fluid : IL-1, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, TGF- beta, TNF-alpha, IL-4 et IFn-gamma.", 
                "measure": "Quantification of inflammation markers in the gingival fluid", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "description": "Assessment of inflammation through Bleeding On Probing", 
                "measure": "Assessment of inflammation", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "description": "Assessment of oral hygiene level with plaque Index", 
                "measure": "Assessment of oral hygiene level", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }
        ], 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}